Roche hemophilia drug wins fast-track FDA designation

ZURICH (Reuters) - Roche said on Friday it had won breakthrough therapy designation from the U.S. Food and Drug Administration for an experimental hemophilia medicine, aiming for a piece of the $11 billion hemophilia drug market.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news